Supplement Scholar
Healing & Repair

Pentadeca Arginate (PDA)

Also: PDA

A BPC-157-derived peptide marketed as a more stable alternative. It has almost no published research of its own.

Discussion
Overview

What it is

Sold since 2024 as a stabilized relative of BPC-157, mainly after compounding pharmacies lost access to BPC-157. Its claims rest on BPC-157's animal research, not studies of PDA itself.

Common forms

Subcutaneous injection (compounded)Oral (compounded)
Mechanism

How it works

Presumed to share BPC-157's proposed actions: new blood-vessel growth via VEGFR2, nitric-oxide modulation, and faster tendon and gut healing in animals.

VEGFR2 signaling (presumed)Nitric oxide system (presumed)
+Tissue repair (extrapolated from BPC-157)
Evidence

What the research supports

Tissue-repair claims extrapolated from BPC-157 animal studiespreclinical
Safety

Side effects & interactions

Side effects

  • Injection-site irritation
  • Unregulated products with unknown purity serious

Medications

  • No notable drug interactions listed.
Stacking

Combines with

Pairs well

  • Nothing specific.

Avoid combining

  • Active cancerNew blood-vessel growth is undesirable when tumors are present.
Community

Discussion

Experiences from people who have tried Pentadeca Arginate (PDA). Anecdotes are not medical advice.

Loading discussion…